Melanotan I vs Palmitoyl Tetrapeptide-7

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Melanotan I

Melanotan I (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe sun sensitivity.

Full details →

Palmitoyl Tetrapeptide-7

Palmitoyl Tetrapeptide-7 is an anti-inflammatory peptide that reduces IL-6 secretion. Combined with Palmitoyl Tripeptide-1, it forms Matrixyl 3000, addressing both collagen production and inflammation.

Full details →

Side-by-Side Comparison

AspectMelanotan IPalmitoyl Tetrapeptide-7
MechanismBinds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection without UV exposure.Suppresses interleukin-6 (IL-6) production, reducing inflammation that contributes to skin aging. The anti-inflammatory effect complements collagen-stimulating peptides.
Typical DosageClinical: 16mg implant every 2 months. Research protocols for tanning typically use 0.5-1mg daily for loading, then maintenance dosing.Topical: Usually combined with Palmitoyl Tripeptide-1 at similar concentrations (2-4%) in the Matrixyl 3000 complex.
AdministrationFDA-approved form is a subcutaneous implant. Research use involves subcutaneous injection. Often combined with minimal UV exposure to enhance results.Topical application with other anti-aging actives. The palmitoyl group enhances delivery into the skin.
Side EffectsNausea (especially initially), facial flushing, fatigue, headache, and darkening of existing moles or freckles.Excellent tolerability profile. Anti-inflammatory properties may actually soothe sensitive skin.
Best For

What They Have in Common

Both Melanotan I and Palmitoyl Tetrapeptide-7 are commonly used for:

Ready to Learn More?